Aica-ribosiduria is a rare genetic condition that affects how the body makes purine building blocks. Features often start in infancy or early childhood and can include developmental delay, low muscle tone, seizures, and feeding difficulties. Doctors describe this as a lifelong condition, and severity can vary from mild to significant disability. Many people with Aica-ribosiduria need supportive care such as seizure control, nutrition support, and developmental therapies. The outlook depends on severity and complications, but with coordinated care some children gain skills and improve comfort over time.
Overview
Aica-ribosiduriaSymptoms
Common features of Aica-ribosiduria include early developmental delay, weak muscle tone, and feeding difficulties in infancy. Seizures and growth problems can occur, sometimes with small head size and distinctive facial features. Eye or vision problems may be present.
Outlook and prognosis
Many living with Aica-ribosiduria grow and learn with supportive therapies, though developmental delays often persist. Seizures, low muscle tone, and coordination issues can be ongoing but vary in severity. Early, consistent care and tailored education improve day-to-day function.
Causes and risk factors
Aica-ribosiduria results from inherited changes in the ATIC gene, usually autosomal recessive. Risk factors for Aica-ribosiduria include having two carrier parents and parental consanguinity. It begins before birth; environment or lifestyle do not cause it, though care may influence complications.
Genetic influences
Genetics is central in Aica-ribosiduria; it results from inherited changes in the ATIC gene. Most cases follow an autosomal recessive pattern, meaning both parents carry a silent variant. Genetic testing confirms the diagnosis and guides family planning and carrier screening.
Diagnosis
Doctors suspect Aica-ribosiduria from clinical features and metabolic screening. Confirmation relies on detecting elevated AICA riboside in urine or blood and by genetic tests. Genetic diagnosis of Aica-ribosiduria supports care planning and family counseling.
Treatment and drugs
Treatment for Aica-ribosiduria focuses on managing symptoms, supporting development, and preventing complications. Care often includes nutrition support, seizure control if needed, therapies for movement and learning, and regular monitoring by genetics and neurology teams. Clinical trials or specialist centers may discuss emerging options.
Symptoms
Aica-ribosiduria is a rare, inherited condition that mostly affects development and the nervous system. Parents often ask about early features of Aica-ribosiduria, which tend to show up in infancy or early childhood as delays in sitting, walking, or speaking. The changes are often subtle at first, blending into daily life until they become more noticeable. Other common features include seizures, low muscle tone, feeding challenges, and growth concerns.
Milestones like rolling, sitting, walking, or first words may come later than expected. Learning new skills can take more repetition and support. Early therapies can make a meaningful difference.
Some children with Aica-ribosiduria have seizures, which may look like staring spells, stiffening, or rhythmic jerks. Seizures can start in infancy or childhood and may vary in frequency. Treatment plans aim to reduce episodes and protect development.
Babies may feel floppy and have trouble holding up the head. Low tone can affect posture, fine motor skills, and stamina. Physical and occupational therapy can help build strength.
Weak suck or trouble coordinating suck–swallow–breathe can make feeding slow. Reflux and frequent gagging can add to the challenge. Nutrition support helps with energy and growth.
How people usually first notice Aica-ribosiduria?
Many families learn something is different in the first months of life when a baby has low muscle tone that makes them feel “floppy,” struggles with feeding, and doesn’t meet early movement milestones as expected. Doctors may notice coarse facial features, an enlarged liver or spleen, and unusual lab findings; over time, caregivers often observe slow developmental progress and seizures that prompt genetic testing. In practice, the first signs of Aica-ribosiduria are these early neuromuscular and developmental concerns that lead clinicians to check purine metabolism and confirm the diagnosis with ALDH7A1 gene testing.
Types of Aica-ribosiduria
Aica-ribosiduria is a rare inherited condition. Variants of Aica-ribosiduria are defined by which step of the same metabolic pathway is affected and how much enzyme activity remains. This helps explain why symptoms can range from developmental differences to seizures and muscle tone changes in some children. Not everyone will experience every type.
ATIC deficiency
This classic form involves very low activity of the ATIC enzyme, which sits at a key step in purine building. Many living with this variant have early developmental delays and low muscle tone, and some experience seizures.
Partial ATIC activity
In this milder clinical variant, the enzyme works at a reduced, but not absent, level. Symptoms may be subtler, such as later motor milestones or learning differences, and seizures are less common.
Biochemical variant
Some people show the typical metabolite pattern on testing but have fewer day‑to‑day symptoms. Researchers describe these categories to better understand patterns of the condition.
Prenatal‑onset features
A small subset shows signs before birth, such as growth restriction or decreased movements, reflecting more severe enzyme shortfall. For many, this can lead to earlier and more noticeable developmental challenges after birth, including feeding or tone issues.
Neonatal‑infantile form
Symptoms appear in the first months with feeding difficulties, low tone, and possible seizures. Certain patterns tend to surface in early infancy, while others emerge later as skills become more complex.
Childhood‑presenting form
Signs are recognized later, often as language or learning concerns and coordination differences. Daily life often makes the differences between symptom types clearer.
Seizure‑predominant course
Some children primarily have seizures with variable developmental impact. Others have fewer or no seizures but more prominent motor or learning challenges.
Motor‑predominant course
Movement and muscle tone differences stand out, with delayed sitting or walking and coordination issues. Cognitive impacts may be milder compared with seizure‑predominant presentations, but school support is often helpful.
Cognitive‑predominant course
Learning, attention, or language challenges are the main concerns, while motor skills and seizures are less affected. Clinicians often describe them in these categories to tailor supports.
Progression spectrum
One type may be strong for a while, then fade as another emerges. The balance of symptoms can shift over time, so tracking changes helps clarify the types of Aica-ribosiduria a child is experiencing.
What genetics can tell you about symptoms
Some people with AICA‑ribosiduria have early developmental delays, seizures, low muscle tone, and distinctive facial features because mutations in the ATIC gene disrupt purine building, which brain and muscles rely on. Certain variants cause more severe enzyme loss, leading to earlier, harder‑to-control symptoms.
Causes and risk factors
Aica-ribosiduria happens when a child inherits two nonworking copies of the ATIC gene.
This autosomal recessive pattern means parents are usually healthy carriers.
The genetic causes of Aica-ribosiduria make risk higher with a family history, known carrier status, or parental relatedness.
Doctors distinguish between risk factors you can change and those you can’t.
Lifestyle or environmental exposures do not cause the condition, but genetic counseling and carrier testing can help people plan and reduce the chance of having an affected child.
Environmental and biological risk factors
Aica-ribosiduria is a very rare condition that begins before birth. Research to date has not identified consistent environmental or pregnancy-related exposures that raise the chance of it occurring. Being exposed to risks in your body or environment doesn’t mean illness is inevitable. Here is what we know right now about environmental and biological risk factors for Aica-ribosiduria, including the overall lack of confirmed links.
Studies have not shown a consistent link between older maternal or paternal age and Aica-ribosiduria. Unlike some chromosomal conditions, risk does not appear to rise with age.
Common pregnancy health issues, such as diabetes or thyroid disease, have not been shown to increase the chance of this condition. Standard prenatal care remains important for overall pregnancy health.
No specific infections during pregnancy have been tied to higher risk. Usual precautions recommended in pregnancy are still wise for general fetal well-being.
Exposure to radiation, heavy metals, or hormone-disrupting chemicals has not been linked to this condition. Avoiding harmful exposures remains good practice for pregnancy health.
Genetic risk factors
Aica-ribosiduria is driven by genetic changes in the ATIC gene that reduce the activity of an enzyme needed to make purines, essential building blocks for cells. It follows an autosomal recessive pattern, meaning a child is affected after inheriting two nonworking copies—one from each parent. Some risk factors are inherited through our genes. Understanding these patterns can guide genetic testing and help families notice early symptoms of Aica-ribosiduria.
ATIC gene variants: Changes (pathogenic variants) in the ATIC gene are the direct cause of Aica-ribosiduria. These changes reduce or block the enzyme’s function in the final steps of purine production.
Purine pathway defect: When ATIC does not work well, certain byproducts build up and the supply of purines drops in cells. This biochemical imbalance underlies the features seen in Aica-ribosiduria.
Autosomal recessive pattern: A child is affected when two nonworking ATIC copies are inherited, one from each parent. In each pregnancy, the chance of Aica-ribosiduria is 25% (1 in 4), and the chance to be an unaffected carrier is 50% (1 in 2).
Carrier parents: Parents of a child with Aica-ribosiduria are typically healthy carriers who each have one nonworking ATIC copy. Carrier testing can identify the specific ATIC change in relatives.
Family history: Having an affected sibling indicates a higher recurrence risk for future children in the same family. Many families have no prior history of Aica-ribosiduria because carriers usually have no symptoms.
Shared ancestry (consanguinity): Parents who are related by blood have a higher chance of carrying the same rare ATIC variant. This increases the likelihood of Aica-ribosiduria in their children.
Variant effect differences: Different ATIC changes may alter enzyme activity to varying degrees. Because Aica-ribosiduria is ultra-rare, the link between specific variants and symptom severity is still limited.
Lifestyle risk factors
Aica-ribosiduria is a rare genetic, congenital condition; lifestyle habits do not cause it, but day‑to‑day choices can influence symptoms like seizures, hypotonia, feeding, and behavior. Focusing on sleep, nutrition, hydration, and appropriately tailored activity can help reduce flares and improve function. The points below describe how lifestyle affects Aica-ribosiduria and what practical habits may ease complications.
Inconsistent or short sleep can lower seizure threshold and worsen daytime irritability. A steady schedule and calming pre‑bed routine may improve seizure control and daytime function.
Prolonged fasting can increase fatigue and may make seizures harder to control. Frequent, nutrient‑dense meals support growth and steadier energy.
Inadequate fluids and fiber can worsen constipation linked to low muscle tone. Good hydration and fiber‑rich foods may reduce discomfort that can disrupt sleep and behavior.
Gentle, therapist‑guided activity can improve hypotonia, balance, and endurance. Better conditioning may support mobility and reduce constipation.
Risk prevention
Aica-ribosiduria is a rare, inherited condition present from birth, so the focus is on reducing complications and supporting healthy development over time. Prevention is about lowering risk, not eliminating it completely. Knowing early symptoms of Aica-ribosiduria—such as slower developmental progress or seizures—and acting quickly can help limit setbacks. Planning ahead with your care team can also make day-to-day life safer and more predictable.
Meet with a genetics specialist to understand how Aica-ribosiduria is inherited. They can explain chances for future children and discuss testing options.
Parents and close relatives can consider carrier testing to clarify family risks. This can guide reproductive decisions and help identify others who might benefit from counseling.
If there is a known family variant, discuss prenatal testing or IVF with embryo testing. These options aim to prevent the condition in future pregnancies.
Regular visits with neurology, genetics, and developmental teams help spot issues early. Consistent monitoring can prevent small concerns from becoming larger complications.
Transmission
Aica-ribosiduria is not contagious—you can’t catch it or pass it through everyday contact. Aica-ribosiduria is a genetic condition that is usually inherited in an autosomal recessive pattern: a child needs two nonworking copies of the gene, one from each parent. Parents who each carry one nonworking copy are typically healthy carriers; with each pregnancy, there is a 25% (1 in 4) chance the child will have Aica-ribosiduria, a 50% (1 in 2) chance the child will be a carrier, and a 25% chance the child will inherit neither changed copy. If you’re wondering about the genetic transmission of Aica-ribosiduria in your family, genetic counseling and carrier testing can clarify risks for future pregnancies.
When to test your genes
Test your genes if you or your child show early signs of developmental delay, seizures, low muscle tone, or unexplained metabolic issues, especially with a family history or consanguinity. Genetic testing confirms AICA‑ribosiduria, guides care, and informs recurrence risk for future pregnancies. Carriers in affected families may also consider testing before conception.
Diagnosis
Diagnosis of Aica-ribosiduria usually starts when developmental delays, seizures, or other early-life concerns prompt a closer look. Family history is often a key part of the diagnostic conversation. Because the condition is very rare, doctors combine clinical features with targeted lab tests and genetic analysis. In some cases, the genetic diagnosis of Aica-ribosiduria is confirmed by identifying changes in the ATIC gene that explain the lab findings.
Doctors look for patterns such as developmental delay, seizures, feeding difficulties, and vision or eye-movement concerns. These features raise suspicion for a neurometabolic condition and guide which tests to order.
Urine and blood tests can measure purine-related compounds using mass spectrometry. A marked rise in AICA-riboside (and sometimes related metabolites) supports Aica-ribosiduria and points to next-step genetic testing.
Sequencing the ATIC gene can confirm the diagnosis by finding disease-causing variants. If initial panels are inconclusive, exome or genome testing may be considered to look wider.
Specialized labs can measure the ATIC enzyme activity in blood cells or cultured skin cells. Very low activity provides functional confirmation that complements genetic results.
Stages of Aica-ribosiduria
Aica-ribosiduria does not have defined progression stages. It is an ultra-rare metabolic condition with signs that usually begin in infancy and a course that can differ widely, so clinicians follow how things change over time rather than assigning stages. Early symptoms of Aica-ribosiduria may include seizures, feeding difficulties, and delayed milestones, which often prompt evaluation and ongoing monitoring. Different tests may be suggested to help confirm the diagnosis, such as checking for a specific buildup in urine or blood and genetic testing to look for changes in the ATIC gene.
Outlook and prognosis
Looking ahead can feel daunting, but most people with Aica-ribosiduria want to know how their health may change over time. Prognosis refers to how a condition tends to change or stabilize over time. In Aica-ribosiduria, the outlook varies a lot because the condition ranges from mild learning differences to significant developmental delays, seizures, and movement challenges. Some children walk and talk later than peers but continue to make steady gains with therapy, while others have more complex needs and require ongoing support at school and at home.
The outlook is not the same for everyone, but careful seizure control, nutrition, and early developmental therapies can improve day-to-day function. Reports suggest that life expectancy can be reduced when seizures are hard to control or when there are feeding and breathing problems, yet many living with Aica-ribosiduria reach adolescence and adulthood, especially with coordinated care. If you’re watching for early symptoms of Aica-ribosiduria in a baby—such as low muscle tone, delayed milestones, or unusual eye movements—getting an early evaluation can open doors to therapies that may change the long-term course. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle.
Everyone’s journey looks a little different. Some people notice gradual progress with periods of plateau, while for others seizures or illnesses cause temporary setbacks. Support from friends and family can make daily routines more manageable and reduce complications linked to stress and poor sleep. Talk with your doctor about what your personal outlook might look like, including seizure risk, nutrition, and ways to support learning across childhood and into adult life.
Long-term effects
Aica-ribosiduria is a rare genetic condition that mainly affects brain development and function over time. Because only a small number of people have been described, the long-term picture is based on limited reports rather than large studies. Long-term effects vary widely, and can range from significant developmental challenges to persistent seizures and vision concerns. Families and clinicians usually focus on how stable key abilities are—like movement, communication, and feeding—as the years go by.
Most children show marked delays in sitting, walking, and learning compared with peers. Early skills may emerge late and remain limited into later childhood and adulthood. Some eventually gain simple daily living abilities with support.
Thinking and problem-solving are often affected from infancy onward. Many live with moderate to severe intellectual disability that continues long term.
Recurrent seizures are common and may begin in early childhood. Some have hard-to-control epilepsy that persists over time.
Low muscle tone in infancy can make head control and posture difficult. Over time, some develop stiffness or spasticity that affects mobility and comfort.
How is it to live with Aica-ribosiduria?
Living with Aica-ribosiduria can feel like moving through days with a lower energy ceiling, where developmental milestones—walking, speaking, learning—often arrive later and need extra support. Many experience low muscle tone, coordination challenges, and intellectual disability, so daily routines may include physical, occupational, and speech therapies, special education planning, and careful management of fatigue. Families and caregivers often become skilled advocates, coordinating appointments and services, while siblings and classmates may need guidance to understand differences and include the child in play and school activities. With consistent supports, clear communication, and a stable routine, many families find a workable rhythm that centers progress, comfort, and connection.
Treatment and drugs
Aica-ribosiduria is very rare, and treatment focuses on easing day-to-day symptoms and supporting growth, development, and comfort. Supportive care can make a real difference in how you feel day to day, which often includes physical, occupational, and speech therapy; nutrition support; seizure management if seizures are present; and vision or hearing services as needed. There’s no approved medicine that corrects the underlying enzyme problem yet, so doctors tailor care to each person’s needs and watch for issues like feeding difficulties, poor weight gain, sleep problems, or movement challenges. Your doctor may suggest anti-seizure drugs, muscle relaxants for stiffness, special feeding plans or tubes for safe nutrition, and devices that aid mobility or communication. Research is ongoing into the gene and metabolic pathway involved, so staying connected with a metabolic or genetics clinic can help you access clinical trials and updated care options.
Non-drug treatment
Non-drug care for Aica-ribosiduria focuses on development, nutrition, and day-to-day function. Because it’s a rare condition, treatments are tailored to each person’s needs and change over time. Beyond prescriptions, supportive therapies can build skills, ease feeding or movement problems, and improve quality of life. Care usually involves a team that works with families across home, school, and clinic.
Starting services early supports learning and motor development. Therapists target movement, language, and play skills. This can also lessen the impact of early symptoms of Aica-ribosiduria.
Improves strength, balance, and coordination. Can reduce stiffness or low tone and help with sitting, standing, and walking.
Builds daily living skills like feeding and dressing. Adapts tasks and tools to match abilities and reduce caregiver strain.
Supports understanding, speaking, and social communication. Can evaluate swallowing and help manage drooling or choking risk.
Your genes may have an impact on how drugs work for you
Medicines for Aica-ribosiduria can work differently depending on variants in genes that handle drug breakdown and transport, affecting dose needs and side effects. Pharmacogenetic testing may guide safer choices, but clinical decisions still rely on symptoms and routine monitoring.
Pharmacological treatments
There’s no disease-specific medicine for Aica-ribosiduria right now, so treatment focuses on easing symptoms and supporting daily function. Not everyone responds to the same medication in the same way. Choices are tailored to the seizures, movement or muscle tone issues, sleep problems, and digestive symptoms someone may have. Plans usually evolve over time as needs change and as doctors see what helps the most.
Levetiracetam, lamotrigine, topiramate, clobazam, or valproate may be used and adjusted based on response. Even when early symptoms of Aica-ribosiduria include seizures, it can take time to find the right regimen. Rescue options like intranasal midazolam or rectal diazepam can help with prolonged events.
Intranasal midazolam or rectal diazepam can stop a long seizure at home or school. Caregivers may help with reminders or keeping track of when a rescue dose was given. Your care team will show you exactly when and how to use them safely.
Baclofen or tizanidine can ease stiff muscles and improve comfort. Botulinum toxin injections may be added for targeted tight muscles. Diazepam is sometimes used short term, with monitoring for sleepiness.
Trihexyphenidyl may help dystonia in some people. Clonazepam or gabapentin can reduce myoclonus or discomfort from abnormal movements. Dosing may be increased or lowered gradually to balance benefit and side effects.
Genetic influences
In Aica-ribosiduria, changes in a gene called ATIC interfere with the body’s ability to make some of the basic building blocks cells use for DNA and energy, which causes a related substance to build up and be passed in the urine. The condition follows an autosomal recessive pattern: a child is typically affected only if they inherit the nonworking gene from both parents. A “carrier” means you hold the gene change but may not show symptoms. If both parents are carriers of the same ATIC change, each pregnancy has a 25% (1 in 4) chance of Aica-ribosiduria, a 50% (1 in 2) chance of a carrier child, and a 25% (1 in 4) chance of a child with no gene change. Genetic testing that looks at the ATIC gene can confirm the diagnosis and clarify risks for parents, siblings, and future pregnancies, including when a child has early symptoms of Aica-ribosiduria. Even within the same family, the features can vary, so results are best reviewed with a genetics specialist.
Is Aica-ribosiduria genetic?
Genetics is central in Aica-ribosiduria; it results from inherited changes in the ATIC gene. Most cases follow an autosomal recessive pattern, meaning both parents carry a silent variant. Genetic testing confirms the diagnosis and guides family planning and carrier screening.
Pharmacogenetics—how genetics influence drug effects
Because Aica-ribosiduria stems from changes in the ATIC gene that disrupt a purine‑building step, treatment choices often focus on avoiding extra stress on that same pathway. In practice, clinicians may use extra caution with medicines that strongly block folate or purine synthesis—such as high‑dose methotrexate, certain chemotherapy agents, or some immunosuppressants—and prefer alternatives or specialist oversight if these are needed. Knowing the exact ATIC result confirms the diagnosis and helps your care team anticipate how pathway‑targeting drugs might behave, even though there isn’t a gene‑guided, disease‑specific medication yet. Not every difference in response is genetic, but your genetic diagnosis adds important context when weighing benefits and risks of any new prescription. Day to day, seizures, stiffness, or feeding issues are usually treated with standard medicines, with doses adjusted to symptoms and side effects rather than the ATIC variant itself. If a drug that affects purine metabolism is truly necessary, doctors typically monitor closely—checking blood counts, liver tests, and clinical response—to reduce the chance of harm.
Interactions with other conditions
People living with Aica-ribosiduria often also manage epilepsy, vision problems, and developmental delays, and these can influence each other day to day. Early symptoms of Aica-ribosiduria such as seizures may flare during common illnesses like colds or with high fever, so preventing infections and treating fevers promptly can help reduce setbacks. A condition may “exacerbate” (make worse) symptoms of another, which is why sleep loss, dehydration, or significant stress sometimes make seizures or behavior changes more noticeable. There can be overlap with other rare purine metabolism disorders, and while they are distinct, they share pathways that can lead to similar neurological features. Some medicines that act on folate or purine pathways—such as methotrexate or certain antifolate drugs—may have stronger-than-expected effects, so specialists typically review any new treatment carefully. Talk with your doctor about how your conditions may influence each other and whether any medication changes are needed before surgeries, vaccinations, or when treating infections.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Families and communities once noticed patterns that puzzled them: babies who fed poorly, children who tired easily, and siblings with similar challenges in growth and learning. Long before tests existed, people with Aica-ribosiduria often saw doctors for repeated infections or developmental delays, while relatives quietly compared notes across generations.
First described in the medical literature as a cluster of unexplained symptoms in the mid–late 20th century, Aica-ribosiduria gradually moved from mystery to a defined metabolic condition. Early reports focused on failure to thrive, muscle weakness, and distinctive facial features doctors observed, but the underlying cause remained unclear. As biochemical testing improved, researchers detected unusual small molecules building up in urine, a clue that the body’s pathway for making purines—the building blocks for DNA and energy transfer—wasn’t working as it should.
From these first observations, scientists began tracing the problem to a single step in that pathway. Careful lab work showed that a specific enzyme acted like a stuck valve, causing AICA riboside and related compounds to accumulate. This finding linked the day-to-day symptoms of Aica-ribosiduria with a concrete biochemical bottleneck, and it allowed clinicians to move beyond describing features to naming the mechanism.
Advances in genetics then tied the enzyme problem to changes in a single gene. What once looked like several separate disorders was recognized as one rare, inherited condition. With DNA testing, families finally had answers about why more than one child might be affected, and clinicians could offer carrier testing to relatives planning a pregnancy. In recent decades, knowledge has built on a long tradition of observation. Laboratories around the world refined urine and blood tests, while genetic panels made diagnosis faster and more precise.
Over time, descriptions became more nuanced. Doctors learned that the early symptoms of Aica-ribosiduria can vary: some babies show feeding difficulties and low muscle tone in the first months, while others present later with developmental delays or seizures. Not every early description was complete, yet together they built the foundation of today’s knowledge. This history also explains why older medical records may use different names or emphasize different features.
Today, the story of Aica-ribosiduria spans careful bedside notes, painstaking chemical studies, and modern gene sequencing. Knowing the condition’s history helps explain current care: early recognition, confirmation with biochemical and genetic testing, and supportive treatments aimed at nutrition, development, and seizure control when needed. It also highlights ongoing efforts to understand how small differences in the gene can shape symptoms, and why some people living with Aica-ribosiduria face more challenges than others.